Chinese Pharmaceutical R&D Takes A Great Leap Forward With FDA Approved Clinical Trials In The U.S.
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - The U.S. Food and Drug Administration has given the green light for Jiangsu Hengrui Medicine to conduct Phase I clinical trials on an innovative diabetes drug in the U.S. This is the first time FDA has approved an application to stage a clinical trial of a China-discovered, synthesized drug
You may also be interested in...
Diabetes And Oncology Drive Interest in China - Shanghai R&D Summit
SHANGHAI - Pharma companies and investors are focusing their interest in China, as they are elsewhere, on diabetes and oncology, but they face unique challenges, according to panelists at a recent R&D conference in Shanghai
Diabetes And Oncology Drive Interest in China - Shanghai R&D Summit
SHANGHAI - Pharma companies and investors are focusing their interest in China, as they are elsewhere, on diabetes and oncology, but they face unique challenges, according to panelists at a recent R&D conference in Shanghai
Merck Sharp & Dohme Launches Januvia In China To Join Race In Second-largest Diabetes Market
SHANGHAI - Having received approval from China's State FDA for Januvia (sitagliptin), Merck Sharp & Dohme announced March 21 that it has launched the dipeptidyl peptidase-4 inhibitor for Type 2 diabetes and joined the race to compete in China's $300 million oral diabetes drug market